Timothy R. Wilson

Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials

Robert C. Doebele, Alexander Drilon, Luis Paz‐Ares et al. · The Lancet Oncology · 2019 · 1.7K citations · Full text

Medicine, Oncology, Metastasis +9

Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors

Timothy R. Wilson, Jane Fridlyand, Yibing Yan et al. · Nature · 2012 · 1.1K citations

Medicine, Cancer Biology, Oncology +16

Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials

Alexander Drilon, Salvatore Siena, Rafał Dziadziuszko et al. · The Lancet Oncology · 2019 · 537 citations · Full text

Medicine, Oncology, Pharmacology +15

The Cancer Stem Cell Marker Aldehyde Dehydrogenase Is Required to Maintain a Drug-Tolerant Tumor Cell Subpopulation

Debasish Raha, Timothy R. Wilson, Jing Peng et al. · Cancer Research · 2014 · 311 citations · Full text

Medicine, Oncology, Pharmacology +17

Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant

Jill M. Spoerke, Steven Gendreau, Kimberly Walter et al. · Nature Communications · 2016 · 297 citations · Full text

Medicine, Genetics, Oncology +17